Skip to main content
Premium Trial:

Request an Annual Quote

Catch by Gene, C&S Ink Supply Agreement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Catch by Gene (CBYG) today announced a reagent supply agreement with C&S.

The deal, which is initially for $300,000, covers CBYG's test kit products for the identification of sexually transmitted diseases, including the early-stage identification of human papillomavirus. CBYG will initially provide C&S with 60,000 reagents a year, and said in a statement that it anticipates that amount to increase each year "with increased demand requirements in addition to other international distributors."

The Korean company develops, manufactures, and markets in vitro nucleic acid assays. Its technology uses multi-probes based on microplate chemiluminescence or colorimetry for the direct detection of infectious pathogens, such as hepatitis B, HPV, and Chlamydia trachomatis, the company said.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.